128 filings
Page 5 of 7
6-K
3al689s ldajd481
23 Apr 20
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
4:00pm
6-K
k2idve6idqxs
14 Apr 20
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
6:41am
6-K
vtwh44uuo5
7 Apr 20
Current report (foreign)
5:30pm
6-K
rl0w0rcw4mmvfg9jo
6 Apr 20
ObsEva SA Announces New Interim Chief Financial Officer
4:00pm
6-K
x9qqwyktbtjq cir
27 Mar 20
Current report (foreign)
7:19am
6-K
2vttcc
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm
6-K
t16prrhgju6s
5 Mar 20
Current report (foreign)
4:10pm
6-K
r8hsjdptv
15 Jan 20
Current report (foreign)
8:35pm
6-K
zg9gvm
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
6-K
2019opui2n75
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
w4rt35nxqf5itcpz hs2
7 Nov 19
Current report (foreign)
9:11am
6-K
qzwcg3cwe n3
31 Oct 19
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical
4:21pm
6-K
l64hp gpd
12 Sep 19
ObsEva announces new composition of its Executive Committee
8:16am
6-K
p3c8gks2ozk9l9md
6 Sep 19
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of
8:27am
6-K/A
enwm7x9
9 Aug 19
Current report (foreign) (amended)
3:22pm
6-K
691vz68dqtym
7 Aug 19
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
4:18pm
6-K
a1d0kkhz
7 Aug 19
Current report (foreign)
7:21am
6-K
5xmdujvmithao89zh1f
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
lmljqbc3t
18 Jul 19
Current report (foreign)
4:05pm
6-K
y7dbbjrd58eychpd
5 Jul 19
Current report (foreign)
6:01pm